Overview

Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to look at the effectiveness of an anti-HIV drug combination that adds capravirine in patients who have failed their first drug combination treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Agouron Pharmaceuticals

Treatments:

Capravirine
Nelfinavir
Reverse Transcriptase Inhibitors